Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Humanigen, Inc. (HGEN)

0.173   0.019 (12.41%) 09-24 15:48
Open: 0.15 Pre. Close: 0.1539
High: 0.177 Low: 0.1476
Volume: 4,288,547 Market Cap: 16(M)
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called 'cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH. It is also developing lenzilumab, which is also being studied in conjunction with CD19-targeted CAR-T cell therapies, as well as exploring the effectiveness of lenzilumab in other inflammatory conditions, such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation and in eosinophilic asthma, and rheumatoid arthritis. In addition, the company focuses on studying lenzilumab for patients with chronic myelomonocytic leukemia exhibiting RAS pathway mutations. Its pipeline also includes two other Humaneered monoclonal antibodies, ifabotuzumab, which binds to EphA3, and HGEN005, which targets EMR1. Ifabotuzumab has been evaluated in a Phase 1 study of glioblastoma multiforme that showed tumor specific targeting of all known tumor sites with no normal tissue uptake. HGEN005 is being explored as a treatment for a range of eosinophilic diseases, including eosinophilic leukemia as an optimized naked antibody and as the backbone for a novel CAR-T construct. Humanigen, Inc. was incorporated in 2000 and is headquartered in Short Hills, New Jersey.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.18 - 0.18 0.18 - 0.18
Low: 0.15 - 0.15 0.15 - 0.15
Close: 0.17 - 0.17 0.17 - 0.18

Technical analysis

as of: 2022-09-23 4:24:44 PM
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 0.31     One year: 0.39
Support: Support1: 0.14    Support2: 0.12
Resistance: Resistance1: 0.26    Resistance2: 0.34
Pivot: 0.19
Moving Average: MA(5): 0.17     MA(20): 0.2
MA(100): 1.23     MA(250): 2.88
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 13.5     %D(3): 6.3
RSI: RSI(14): 28.7
52-week: High: 8.38  Low: 0.14
Average Vol(K): 3-Month: 9,994 (K)  10-Days: 3,775 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ HGEN ] has closed above bottom band by 21.9%. Bollinger Bands are 90.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 37 bars. This is a sign that the market may be about to initiate a new trend.

Headline News

Fri, 23 Sep 2022
HGEN SHAREHOLDER ALERT: Jakubowitz Law Reminds Humanigen Shareholders of a Lead Plaintiff Deadline of October 25, 2022 - PR Newswire

Thu, 22 Sep 2022
HGEN, CPNG & SFIX Class Actions: Bronstein, Gewirtz & Grossman, LLC, A Leading Class Action Firm, Reminds Investors to Contact the Firm and Actively Participate - Coupang (NYSE:CPNG), Humanigen (NASDAQ:HGEN) - Benzinga

Tue, 20 Sep 2022
Where Does Wall Street Think Humanigen Inc (HGEN) Stock Will Go? - InvestorsObserver

Tue, 20 Sep 2022
Humanigen, Inc. Class Action Alert: Shareholders with Losses in Humanigen, Inc. (HGEN) Are Urged to Conta - Benzinga

Tue, 20 Sep 2022
HUMANIGEN, INC. (NASDAQ:HGEN) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of - Benzinga

Mon, 19 Sep 2022
Stocks of Humanigen Inc. (HGEN) are poised to climb above their peers - SETE News

Financial Analysis

Price to Book Value: Underperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 64 (M)
% Held by Insiders 5.48e+007 (%)
% Held by Institutions 20.1 (%)
Shares Short 6,410 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -4
Return on Assets (ttm) 557.4
Return on Equity (ttm) -138.8
Qtrly Rev. Growth 4.14e+006
Gross Profit (p.s.) 0
Sales Per Share 0.04
EBITDA (p.s.) 0
Qtrly Earnings Growth -2.5
Operating Cash Flow 0 (M)
Levered Free Cash Flow -168 (M)

Stock Valuations

PE Ratio 0
PEG Ratio -0.1
Price to Book value 0
Price to Sales 3.58
Price to Cash Flow -0.16

Stock Dividends

Dividend 0
Forward Dividend 8.34e+006
Dividend Yield 0%
Dividend Pay Date 2020-09-13
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.